PDS Biotechnology Corporation
PDS Biotechnology Corporation
Your view on PDSB
Overview
What the company does, where it operates, and who runs it.
About PDS Biotechnology Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Frank K. Bedu-Addo
- Headquarters
- 25B Vreeland Road, Princeton, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Frank K. Bedu-Addo
- Headquarters
- 25B Vreeland Road, Princeton, NJ, US
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies.
Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.
The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma.
In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH.
PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for PDS Biotechnology Corporation, and the rating behind it. PDSB last traded at $0.29; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for PDS Biotechnology Corporation. Starting points for PDS Biotechnology Corporation: EPS -$0.60, beta 1.45 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for PDS Biotechnology Corporation. PDS Biotechnology Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for PDS Biotechnology Corporation. Trailing twelve-month EPS for PDS Biotechnology Corporation stands at -$0.60. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for PDS Biotechnology Corporation. PDS Biotechnology Corporation has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
PDS Biotechnology Corporation valued side by side against its closest peers. PDS Biotechnology Corporation is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold PDS Biotechnology Corporation, and how their positions are changing. At a $16.5M market value, institutional positions materially move PDS Biotechnology Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by PDS Biotechnology Corporation executives and directors. Shares of PDS Biotechnology Corporation have traded between $0.76 and $2.46 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming PDS Biotechnology Corporation. PDS Biotechnology Corporation is a $16.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming PDS Biotechnology Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for PDS Biotechnology Corporation. Coverage tracks PDS Biotechnology Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.